REZDIFFRA, a thyroid hormone receptor-beta agonist, is indicated for treating noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis in conjunction with diet and exercise, based on improvement in NASH and fibrosis.

Therapeutic Effect of REZDIFFRA in NASH Treatment

REZDIFFRA (resmetirom) is primarily indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) accompanied by moderate to advanced liver fibrosis, specifically stages F2 to F3. The therapeutic benefit of REZDIFFRA lies in its ability to improve both the clinical and histological aspects of NASH and liver fibrosis, thereby providing a significant reduction in liver inflammation and fibrosis progression. As a thyroid hormone receptor-beta (THR-beta) agonist, it modulates liver metabolism, improving fat accumulation and fibrosis markers. This treatment approach is especially beneficial when combined with lifestyle interventions such as diet and exercise. The drug’s approval is based on accelerated clinical trials showing improvement in liver histology, although continued approval depends on further confirmatory studies regarding long-term efficacy and safety.